Calliditas Therapeutics AB (publ)
CALT
Cena:
Valuace
100
Růst
45
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
DELISTING OF CALLIDITAS THERAPEUTICS AB (PUBL) FROM NASDAQ STOCKHOLM
16-09-2024
STOCKHOLM , SEPT. 16, 2024 /PRNEWSWIRE/ -- NASDAQ STOCKHOLM HAS DECIDED THAT CALLIDITAS THERAPEUTICS...
Více zde
NOTICE OF EXTRAORDINARY MEETING OF CALLIDITAS THERAPEUTICS AB (PUBL)
03-09-2024
STOCKHOLM , SEPT. 3, 2024 /PRNEWSWIRE/ -- THE SHAREHOLDERS OF CALLIDITAS THERAPEUTICS AB (PUBL) ("C...
Více zde
CALLIDITAS THERAPEUTICS TAKES CERTAIN CORPORATE ACTIONS FOLLOWING ANNOUNCEMENT BY ASAHI KASEI
03-09-2024
STOCKHOLM , SEPT. 3, 2024 /PRNEWSWIRE/ -- FOLLOWING THE ANNOUNCEMENT BY ASAHI KASEI CORPORATION ("AS...
Více zde
CALLIDITAS INTERIM REPORT JANUARY TO JUNE 2024
13-08-2024
STOCKHOLM , AUG. 13, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (STO: CALTX) : A...
Více zde
NUMBER OF SHARES AND VOTES IN CALLIDITAS THERAPEUTICS
31-07-2024
STOCKHOLM , JULY 31, 2024 /PRNEWSWIRE/ -- DURING JULY, THE NUMBER OF SHARES AND VOTES IN CALLIDITAS...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES ATRI, CALT ON BEHALF OF SHAREHOLDERS
28-07-2024
NEW YORK, NY / ACCESSWIRE / JULY 28, 2024 / HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVEST...
Více zde
STOCKHOLDER ALERT: THE M&A CLASS ACTION FIRM IS INVESTIGATING THE MERGER AND ITS TENDER OFFER FOR CALLIDITAS THERAPEUTICS AB – CALT
27-07-2024
NEW YORK, JULY 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, JULY 27, 2024 / GLOBENEWSWIRE/-- MONTEVERDE & ...
Více zde
STOCKHOLDER ALERT: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF THE MERGER AND ITS TENDER OFFER, EXPIRING AUGUST 30, 2024, FOR SHARES OF CALLIDITAS THERAPEUTICS AB - CALT
26-07-2024
NEW YORK , JULY 26, 2024 /PRNEWSWIRE/ -- MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"), H...
Více zde
CALLIDITAS ANNOUNCES POSITIVE TRANSFORM PHASE 2B TOPLINE DATA IN PRIMARY BILIARY CHOLANGITIS
26-07-2024
STOCKHOLM , JULY 26, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (STOCKHOLM: CALT...
Více zde
LAUNCH OF PHASE 3 CLINICAL TRIAL WITH NEFECON IN JAPAN
04-07-2024
STOCKHOLM , JULY 4, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (STO: CALTX) ("CA...
Více zde
CALLIDITAS PROVIDES SETANAXIB PATENT UPDATE
18-06-2024
STOCKHOLM , JUNE 18, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOL...
Více zde
BULLETIN FROM THE ANNUAL GENERAL MEETING OF CALLIDITAS THERAPEUTICS AB (PUBL)
17-06-2024
STOCKHOLM , JUNE 17, 2024 /PRNEWSWIRE/ -- THE FOLLOWING RESOLUTIONS WERE PASSED AT CALLIDITAS THERA...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES AKLI, CALT, SGE ON BEHALF OF SHAREHOLDERS
07-06-2024
NEW YORK, JUNE 07, 2024 (GLOBE NEWSWIRE) -- HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVEST...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES AKLI, CALT ON BEHALF OF SHAREHOLDERS
06-06-2024
NEW YORK, NY / ACCESSWIRE / JUNE 6, 2024 / HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTI...
Více zde
STOCKHOLDER ALERT: THE M&A CLASS ACTION FIRM INVESTIGATES MERGER AND EXPIRING TENDER OFFER - AKLI AND CALT
06-06-2024
NEW YORK, NY / ACCESSWIRE / JUNE 6, 2024 / MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"),...
Více zde
STOCKHOLDER INVESTIGATION: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF THE MERGER AND ITS TENDER OFFER, EXPIRING JULY 18, 2024, FOR SHARES OF CALLIDITAS THERAPEUTICS AB – CALT
05-06-2024
NEW YORK, JUNE 05, 2024 (GLOBE NEWSWIRE) -- MONTEVERDE & ASSOCIATES PC (THE “M&A CLASS ACTION FIRM...
Více zde
SHAREHOLDER UPDATE: HALPER SADEH LLC CONTINUES TO INVESTIGATE MODN, CALT
04-06-2024
NEW YORK, NY / ACCESSWIRE / JUNE 4, 2024 / HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTI...
Více zde
STOCKHOLDER INVESTIGATION: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF THE MERGER AND ITS TENDER OFFER, EXPIRING JULY 18, 2024, FOR SHARES OF CALLIDITAS THERAPEUTICS AB - CALT
04-06-2024
NEW YORK , JUNE 4, 2024 /PRNEWSWIRE/ -- MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"), HA...
Více zde
CALLIDITAS PARTNER STADA RECEIVES POSITIVE CHMP OPINION RECOMMENDING FULL APPROVAL FOR KINPEYGO® FOR THE TREATMENT OF IGA NEPHROPATHY
30-05-2024
STOCKHOLM , MAY 30, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOLM...
Více zde
CALLIDITAS THERAPEUTICS PRESENTS DATA AT THE 61ST EUROPEAN RENAL ASSOCIATION CONGRESS
28-05-2024
STOCKHOLM , MAY 28, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOLM...
Více zde
CALT STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF CALLIDITAS THERAPEUTICS AB IS FAIR TO SHAREHOLDERS
28-05-2024
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
STATEMENT BY THE BOARD OF DIRECTORS OF CALLIDITAS THERAPEUTICS AB (PUBL) IN RELATION TO THE PUBLIC OFFER BY ASAHI KASEI CORPORATION
28-05-2024
STOCKHOLM , MAY 28, 2024 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF CALLIDITAS THERAPEUTICS AB (PUBL...
Více zde
IN-PERSON & VIRTUAL R&D DAY: THE ANTI-FIBROTIC EFFECTS OF SETANAXIB AND TARPEYO'S MODE OF ACTION
16-05-2024
STOCKHOLM , MAY 16, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOLM...
Více zde
CALLIDITAS THERAPEUTICS TO PRESENT DATA AT ERA 2024 MAY 23 - 26 IN STOCKHOLM
15-05-2024
STOCKHOLM , MAY 15, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOLM...
Více zde
NOTICE OF ANNUAL GENERAL MEETING OF CALLIDITAS THERAPEUTICS AB (PUBL)
15-05-2024
STOCKHOLM , MAY 15, 2024 /PRNEWSWIRE/ -- THE SHAREHOLDERS OF CALLIDITAS THERAPEUTICS AB (PUBL) ("CA...
Více zde
CALLIDITAS' PARTNER EVEREST MEDICINES STARTS COMMERCIAL LAUNCH OF NEFECON IN CHINA
14-05-2024
STOCKHOLM , MAY 14, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOL...
Více zde
CALLIDITAS ANNOUNCES POSITIVE TOPLINE RESULTS OF PHASE 2 HEAD AND NECK CANCER TRIAL WITH LEAD NOX INHIBITOR CANDIDATE, SETANAXIB
06-05-2024
STOCKHOLM , MAY 6, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHOLM:...
Více zde
CALLIDITAS THERAPEUTICS' 2023 ANNUAL REPORT PUBLISHED
24-04-2024
STOCKHOLM , APRIL 24, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT), (NASDAQ STOCKH...
Více zde
CALLIDITAS ANNOUNCES POSITIVE NEFIGARD OPEN LABEL EXTENSION RESULTS
24-04-2024
STOCKHOLM , APRIL 24, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT), (NASDAQ STOCKH...
Více zde
CALLIDITAS THERAPEUTICS PRESENTS ADDITIONAL DATA ANALYSES FROM THE PHASE 3 NEFLGARD TRIAL OF NEFECON IN PRIMARY IGA NEPHROPATHY AT THE ISN WORLD CONGRESS OF NEPHROLOGY 2024
18-04-2024
STOCKHOLM , APRIL 18, 2024 /PRNEWSWIRE/ -- CALLIDITAS THERAPEUTICS AB (NASDAQ: CALT) (NASDAQ STOCKHO...
Více zde
Dokumenty nejsou k dispozici
